Drugs / VIS171
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06799520 | Mar 2025 → Dec 2026 expected | alopecia areata, focal segmental glomerulosclerosis, systemic lupus erythematosus | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05418101 | Apr 2022 → Mar 2024 | autoimmune disease | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIS171 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05418101 ↗ |
| Route | Subcutaneous | “via SC route of administration” NCT05418101 ↗ |